Clinical trials: Therapy-related Toxicity
Head and Neck Cancer
Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer
Radiotherapy is an integral component of the current multimodality treatment approach in locally advanced head and neck cancer (HNC).
- Trial name
- PRETOXIS (NCT02103010)
- Where
- 2 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- University Hospital, Ghent
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Cancer, Systemic Treatment
Systemic Treatment Related Toxicity Identified With a Smartphone APPlication Measuring Step Count
The goal of this observational study is to investigate whether daily physical activities measured with a smartphone are related to the possible side effects or other physical complaints that arise as a result of cancer treatment.
- Conditions
- Cancer, Systemic Treatment, Physical Activity, Toxicity Due to Chemotherapy
- Trial name
- STAPPS (NCT05927636)
- Where
- 3 sites in Netherlands
- Volunteers
- 411 people
- Sponsor
- Radboud University Medical Center
Metastatic Breast Cancer, Toxicity
PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment
On March 17th, 2011, the European Commission issued a marketing authorization valid throughout the European Union for Eribulin mesylate (Halaven; Eisai Limited), for the treatment of patients with locally advanced or metastatic…
- Conditions
- Metastatic Breast Cancer, Toxicity, Neurotoxicity, Drug Toxicity
- Trial name
- NCT02864030
- Testing
- ERIBULIN MESYLATE
- Where
- 20 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Oncologia Medica dell'Ospedale Fatebenefratelli
Cytokine Release Syndrome, ICANS
Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study
This Phase I, prospective, single-arm clinical study aims to evaluate the efficacy and safety of adjunctive methylene blue (MB) in patients experiencing cytokine release syndrome (CRS) or immune effector cell-associated…
- Trial name
- NCT07169487
- Testing
- Methylene Blue
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-Hodgkin's Lymphoma, Hodgkin's Disease
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma
This is an open label pilot study of 40 evaluable patients receiving vinorelbine-gemcitabine combination chemotherapy with filgrastim support in an outpatient setting.
- Trial name
- NCT00163748
- Testing
- gemcitabine, vinorelbine
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Bayside Health
Cocaine Use, Cocaine Intoxication
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department…
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse
- Trial name
- CATALYST (NCT06045793)
- Testing
- TNX-1300 (Injection)
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Graves Disease, Graves Ophthalmopathy
Liver Function After Intravenous Methylprednisolone Administration
Graves' orbitopathy (GO) is a characterized by orbital soft tissue inflammation and oedema associated with glycosaminoglycan deposition and fibrosis. The most frequent cause is Graves' disease.
- Conditions
- Graves Disease, Graves Ophthalmopathy, Liver Diseases, Liver Failure
- Trial name
- NCT03667157
- Testing
- every week IVMP therapy, very high doses IVMP therapy
- Volunteers
- 68 people
- Sponsor
- Medical University of Warsaw
Toxic Optic Neuropathy, Treatment
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial.
The goal of this double-blind prospective randomized clinical trial is to determine if the effect of intravenous erythropoietin is superior to the effect of intravenous methylprednisolone in cases of toxic optic neuropathy 4…
- Conditions
- Toxic Optic Neuropathy, Treatment, Methylprednisolone, Erythropoietin
- Trial name
- NCT05748561
- Testing
- Recombinant human erythropoietin 4,000 UI and 2,000 UI, Methylprednisolone succinate 500 mg
- Where
- Mexico
- Volunteers
- 18 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Cardiovascular Diseases, Cardiotoxicity
Cancer Treatment Related Cardiovascular Toxicity: Comprehensive Myocardial and Vascular Phenotyping
Observational prospective cohort study designed to assess the mechanisms of fluoropyrimidine induced cardiovascular toxicity.
- Conditions
- Cardiovascular Diseases, Cardiotoxicity, Fluorouracil Adverse Reaction, Malignancy
- Trial name
- PC-TOX (NCT06048458)
- Testing
- Cardiovascular magnetic resonance with stress perfusion, CT coronary angiography, Retinal OCT angiography
- Where
- United Kingdom
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University College, London
Hand Foot Skin Syndrome
Topical Cosmetic Products for Hand and Foot Syndrome
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing…
- Trial name
- NCT06586073
- Testing
- cosmetic products
- Where
- Italy
- Volunteers
- 53 people
- Sponsor
- Dermophisiologique s.r.l
Stevens - Johnson Syndrome
G-CSF in the Treatment of Toxic Epidermal Necrolysis
NeupoNET aims to evaluate interest of G-CSF in the treatment of Toxic Epidermal necrolysis. This is a prospective randomized controlled trial.
- Trial name
- NeupoNET (NCT02739295)
- Testing
- recombinant granulocyte - colony stimulating factor, NaCl 0.9%
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University of Liege
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003268
- Testing
- amifostine trihydrate, cytarabine, idarubicin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Melanoma
Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older
This phase I trial studies the side effects of adding anakinra and tocilizumab to standard treatment with nivolumab and ipilimumab and to see how well it works in treating melanoma patients who are 50 years of age or older.
- Trial name
- NCT07838974
- Testing
- Anakinra, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Southern California
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Radiation Toxicity
- Trial name
- NCT00003251
- Testing
- amifostine trihydrate, cisplatin, paclitaxel
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Illinois Chicago
Cancer (Solid Tumors), Geriatric Oncology
TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer
Older adults receiving systemic cancer treatments are at increased risk of developing severe treatment-related toxicities (TRT).
- Trial name
- NCT07484932
- Testing
- TRTRM-guided risk-stratified treatment strategy
- Where
- Hong Kong
- Volunteers
- 400 people
- Sponsor
- The University of Hong Kong
Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity
Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029.
The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr.
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound Healing
- Trial name
- EPOOzo-2 (NCT07325851)
- Testing
- Ozone Therapy
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Bernardino Clavo, MD, PhD
Musculoskeletal Complication, Recurrent Breast Carcinoma
Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer
This pilot clinical trial studies questionnaires in identifying arms, shoulder, and neck (upper extremity) function and quality of life after treatment in patients with breast cancer.
- Conditions
- Musculoskeletal Complication, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer
- Trial name
- NCT02370264
- Testing
- Quality-of-Life Assessment, Questionnaire Administration, Medical Chart Review
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Southern California
Toxic Epidermal Necrolysis
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis
- Trial name
- TEN (NCT06119490)
- Testing
- Abrocitinib, Tofacitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peng Zhang
Breast Cancer
Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity
This was a phase III, randomized, double blind, multicenter, 2-arm study evaluating the efficacy and safety of amcenestrant compared with tamoxifen in participants with hormone receptor-positive early breast cancer who…
- Trial name
- AMEERA-6 (NCT05128773)
- Testing
- Amcenestrant, Tamoxifen
- Where
- 2 sites in Chile, China
- Volunteers
- 3 people
- Sponsor
- Sanofi